About US
Contact us
-
Pharma continues parachute-building for patent cliffLast month was a big one for pharma dealmaking, as anyone following the industry knows well. The list of deals, bids and potential deals is long--$33 billion long, as Dealogic tells the Financial Time2012/5/8
-
Roche gives up on anticipated 'good cholesterol' drugRoche's ($RHHBY) once-promising "good cholesterol" drug candidate is now history. The Swiss company stopped development of dalcetrapib after it fell short in a late-stage trial. Coupled with the failu2012/5/8
-
Pfizer, Lilly, AstraZeneca giving NIH abandoned drugsThree of the world's largest drug manufacturers are going to empty out their closets and turn over research on unsuccessful drugs to the National Institutes of Health. The idea is that federally funde2012/5/7
-
India's Cipla puts fire-sale prices on cancer drugsIn what appears as a full-on assault on the pricing structure of Western drugmakers, Indian genericsmaker Ciplawill sell its copies of cancer drugs for a fraction of their branded counterparts. Cipla2012/5/7
-
Teva exec: Euro price cuts may trigger generics shortagesEuropean price-cutting has caused many a branded drugmaker to lament. Now, generics giant Teva Pharmaceutical Industries ($TEVA) is getting into the act. The company's European chief warned that squee2012/5/4
-
IOM takes FDA to task on post-marketing safetyThe FDA doesn't do enough to track drugs' safety after they're on the market, government watchdogs at the Institute of Medicine say. To prevent another Vioxx-esque disaster, FDA should periodically2012/5/4
-
SFDA issues notice on effective utilization of ADR monitoring dataThe State Food and Drug Administration (SFDA) recently issued a notice on effective utilization of adverse drug reaction (ADR) monitoring data. The notice requires to make effective analysis, evaluati2012/5/2
-
SFDA further defines time limits for ophthalmic preparations to meet the requirements of newly revised GMPThe State Food and Drug Administration (SFDA) recently issued a notice to further define time limits for ophthalmic preparations and related products to meet the requirements of newly revised GMP.In a2012/5/2
-
Novartis digs into safety data in Avastin-vs.-Lucentis studyNovartis ($NVS) couldn't let the Avastin-vs.-Lucentis study pass by without comment. Two-year data from that head-to-head trial, funded by the National Eye Institute, showed that the two drugs were ev2012/5/3
-
Pfizer settles Celebrex royalty suit for $450MIt took almost 6 years, but Pfizer ($PFE) and Brigham Young University have finally come to terms. The drugmaker agreed to pay $450 million to settle a lawsuit claiming that BYU deserved billions in r2012/5/3